Pulmonary hypertension in pregnancy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pulmonary hypertension describes a clinical condition caused by different cardiopulmonary diseases. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive conditions characterized by right ventricular failure and increased pulmonary artery pressures that are clinically challenging to manage in the pregnant patient. This chapter reviews diagnosis and management of the pregnant patient with PAH or CTEPH. Initial recognition of pulmonary hypertension frequently occurs with use of transthoracic echocardiography. Transthoracic echocardiography is an easily accessible, noninvasive screening test for pulmonary hypertension. Calcium channel antagonists and PAH-specific therapies have been reported to improve exercise capacity, reduce symptoms, and improve survival in non-pregnant patients with PAH. CTEPH is a disease state that develops as a result of recurrent pulmonary emboli that occlude the pulmonary vasculature, leading to pulmonary hypertension. Management of CTEPH is based on anticoagulation treatment with warfarin. However, in the pregnant patient, warfarin should be discontinued due to the teratogenic effects on the fetus.

Original languageEnglish (US)
Title of host publicationCritical Care Obstetrics
Publisherwiley
Pages775-790
Number of pages16
ISBN (Electronic)9781119129400
ISBN (Print)9781119129370
DOIs
StatePublished - Jan 1 2018

Fingerprint

Pulmonary Hypertension
Pregnancy
Warfarin
Echocardiography
Lung
Calcium Channel Blockers
Embolism
Pulmonary Artery
Fetus
Exercise
Pressure
Survival

Keywords

  • Chronic thromboembolic pulmonary hypertension
  • PAH-specific therapies
  • Pregnant patient
  • Pulmonary arterial hypertension
  • Pulmonary hypertension
  • Transthoracic echocardiography
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pulmonary hypertension in pregnancy. / Zaidan, Mohammed Fathi; Duarte, Alexander.

Critical Care Obstetrics. wiley, 2018. p. 775-790.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zaidan, Mohammed Fathi ; Duarte, Alexander. / Pulmonary hypertension in pregnancy. Critical Care Obstetrics. wiley, 2018. pp. 775-790
@inbook{54201e8cebea452b833a4d6cebf83e2f,
title = "Pulmonary hypertension in pregnancy",
abstract = "Pulmonary hypertension describes a clinical condition caused by different cardiopulmonary diseases. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive conditions characterized by right ventricular failure and increased pulmonary artery pressures that are clinically challenging to manage in the pregnant patient. This chapter reviews diagnosis and management of the pregnant patient with PAH or CTEPH. Initial recognition of pulmonary hypertension frequently occurs with use of transthoracic echocardiography. Transthoracic echocardiography is an easily accessible, noninvasive screening test for pulmonary hypertension. Calcium channel antagonists and PAH-specific therapies have been reported to improve exercise capacity, reduce symptoms, and improve survival in non-pregnant patients with PAH. CTEPH is a disease state that develops as a result of recurrent pulmonary emboli that occlude the pulmonary vasculature, leading to pulmonary hypertension. Management of CTEPH is based on anticoagulation treatment with warfarin. However, in the pregnant patient, warfarin should be discontinued due to the teratogenic effects on the fetus.",
keywords = "Chronic thromboembolic pulmonary hypertension, PAH-specific therapies, Pregnant patient, Pulmonary arterial hypertension, Pulmonary hypertension, Transthoracic echocardiography, Warfarin",
author = "Zaidan, {Mohammed Fathi} and Alexander Duarte",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/9781119129400.ch46",
language = "English (US)",
isbn = "9781119129370",
pages = "775--790",
booktitle = "Critical Care Obstetrics",
publisher = "wiley",

}

TY - CHAP

T1 - Pulmonary hypertension in pregnancy

AU - Zaidan, Mohammed Fathi

AU - Duarte, Alexander

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Pulmonary hypertension describes a clinical condition caused by different cardiopulmonary diseases. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive conditions characterized by right ventricular failure and increased pulmonary artery pressures that are clinically challenging to manage in the pregnant patient. This chapter reviews diagnosis and management of the pregnant patient with PAH or CTEPH. Initial recognition of pulmonary hypertension frequently occurs with use of transthoracic echocardiography. Transthoracic echocardiography is an easily accessible, noninvasive screening test for pulmonary hypertension. Calcium channel antagonists and PAH-specific therapies have been reported to improve exercise capacity, reduce symptoms, and improve survival in non-pregnant patients with PAH. CTEPH is a disease state that develops as a result of recurrent pulmonary emboli that occlude the pulmonary vasculature, leading to pulmonary hypertension. Management of CTEPH is based on anticoagulation treatment with warfarin. However, in the pregnant patient, warfarin should be discontinued due to the teratogenic effects on the fetus.

AB - Pulmonary hypertension describes a clinical condition caused by different cardiopulmonary diseases. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive conditions characterized by right ventricular failure and increased pulmonary artery pressures that are clinically challenging to manage in the pregnant patient. This chapter reviews diagnosis and management of the pregnant patient with PAH or CTEPH. Initial recognition of pulmonary hypertension frequently occurs with use of transthoracic echocardiography. Transthoracic echocardiography is an easily accessible, noninvasive screening test for pulmonary hypertension. Calcium channel antagonists and PAH-specific therapies have been reported to improve exercise capacity, reduce symptoms, and improve survival in non-pregnant patients with PAH. CTEPH is a disease state that develops as a result of recurrent pulmonary emboli that occlude the pulmonary vasculature, leading to pulmonary hypertension. Management of CTEPH is based on anticoagulation treatment with warfarin. However, in the pregnant patient, warfarin should be discontinued due to the teratogenic effects on the fetus.

KW - Chronic thromboembolic pulmonary hypertension

KW - PAH-specific therapies

KW - Pregnant patient

KW - Pulmonary arterial hypertension

KW - Pulmonary hypertension

KW - Transthoracic echocardiography

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85060654112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060654112&partnerID=8YFLogxK

U2 - 10.1002/9781119129400.ch46

DO - 10.1002/9781119129400.ch46

M3 - Chapter

SN - 9781119129370

SP - 775

EP - 790

BT - Critical Care Obstetrics

PB - wiley

ER -